Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 117Terminated 38Unknown 15Withdrawn 8Active not recruiting 2Approved for marketing 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2Head & Neck 1

Conditions

Breast Neoplasms 2Patient Compliance 1

Interventions

Paclitaxel 83Fulvestrant 65Trastuzumab 62Letrozole 61pembrolizumab 53Carboplatin 51Cyclophosphamide 48pertuzumab 46palbociclib 44Anastrozole 41Capecitabine 33Tamoxifen 30Magnetic Resonance Spectroscopy 29exemestane 28Radiotherapy 28Doxorubicin 28ribociclib 26olaparib 26Docetaxel 26Specimen Handling 25abemaciclib 24130-nm albumin-bound paclitaxel 20trastuzumab deruxtecan 19Taxes 19Gemcitabine 19durvalumab 18Surveys and Questionnaires 18Epirubicin 18eribulin 17Alpelisib 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Lapatinib × Breast × Clear all
NCT01273610 2025-06-10

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

City of Hope Medical Center

Phase 2 Active not recruiting
40 enrolled 15 charts
Breast

Breast Neoplasms, Patient Compliance

NCT00999804 2025-03-12

HELEX

Baylor Breast Care Center

Phase 2 Active not recruiting
128 enrolled 11 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡